Viral Vectors

Consistent, cGMP-Compliant & Fully Scalable Production of Viral Vectors


Increase productivity and reduce costs by harnessing the power of the only delivery platform that scales from bench to biomanufacturing and offers a clear regulatory pathway for use of viral vectors in pre-clinical & clinical studies as well as patient treatment.

  • Rapid high titer production of lentivirus and AAV vectors
  • Highly efficient, reproducible transfection of commonly used adherent & suspension cell lines
  • Capable of efficiently delivering multiple and/or large plasmids
  • Computer-controlled, closed environment for consistent results
  • Clear regulatory pathway – cGMP compliant and FDA Master File


One Technology with Bench to Biomanufacturing Scalability

Perform high quality (co)transfection of adherent and suspension cells from starting volumes of less than 100 microliters up to multi-liter volumes using a regulatory-compliant delivery platform and single-use processing assemblies for rapid, high titer “plug-and-play” viral vector production, including vectors derived from lentivirus, adenovirus, adeno-associated virus and alphavirus.







Seamlessly Scale from R&D to Bioproduction without the Need for Reoptimization


Suspension-adapted HEK 293FT cells were co-transfected with 5 plasmid (lentivector system) via small- or large-scale electroporation on the MaxCyte STX or on the MaxCyte VLX.  Identical electroporation protocols were used on both instruments.  Transfected cells were seeded into shake flasks or WAVE Cellbags at 4e6/mL post transfection. Media was collected and lentivirus infectious units measured 24 hours post transfection.

Consistent, cGMP-Compliant, Large-Scale Lentivirus Manufacturing


Suspension-adapted HEK 293FT cells were co-transfected with 4 plasmids (HIV-based lentivector system) during three independent production runs using the MaxCyte STX.  Cells were cultured post electroporation in 10-L Cellbag in a Wave Bioreactor in a final volume of 2.1 – 2.3 litters.  Media was collected 48 hours post electroporation and infectious units measured.  *See Human Gene Therapy (2012) 23:243-249 for detailed methodology and full study results.

Rapid, High Titer AAV Production Enable Significant Cost Savings


Adherent HEK cells were cotransfected with plasmids expressing an AAV2 vector on the MaxCyte STX. Media were collected at Day 1, 2 and 3 post electroporation and AAV titers measured. The ability to harvest on day 2 enables significant cost savings for large-scale manufacturing in a GMP facility.

Improved AAV Productivity vs PEI for Adherent & Suspension Cells


Adherent or suspension-adapted HEK cells were cotransfected with plasmids expressing either AAV8 or AAV2 via MaxCyte electroporation or PEI. Both transfection methods were performed on the same days using the same cells and plasmids. MaxCyte results show a 2.4- to 10-fold increase in AAV titers when compared with PEI.

Consistent Production of AAV


Adherent HEK cells were cotransfected with plasmids expressing AAV8 on three separate days. Media were collected and AAV titers determined 24 hours post transfection.

Resource Center

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Request Demo